Despite recent advances in the therapy of ovarian malignancy, ovarian carcinoma is the most lethal of all gynaecological carcinomas. Because of an insidious disease arising from a deep-seated organ, initial detection is often delayed. The common epithelial ovarian carcinomas constitute the vast majority of all ovarian cancers (Petterson, 1985) .
A large number of monoclonal antibodies (Mabs) against ovarian carcinoma have been produced using hybridoma technology, mainly by immunising mice with cancer cell lines or their extracts, in an attempt to identify tumour-specific or tissue-specific markers (Sakakibara et al., 1988; Nakagawa et al., 1987; Miotti et al., 1985 Miotti et al., , 1987 Mattes et al., 1984 Mattes et al., , 1987 Tsuji et al., 1985; Tagliabue et al., 1985; Croghan et al., 1984; Bhattacharya et al., 1982; Bast et al., 1981) . As yet, however, none of the antigens identified appears to be tumour-specific. The expression of ovarian and other cancer associated antigen(s) recognised by Mab(s) has been frequently detectable in normal tissues, especially in fetal tissues, by further extensive screening procedures. In this sense, some cancer associated antigens have been considered to be oncodevelopmental and/or tissue differentiation antigens (Feizi, 1985; O'Brien et al., 1986) . Therefore, we have taken an alternative approach, i.e. immunised mice with embryonal tissues from fetus in early first trimester, given booster injections of an ovarian cancer cell line. The aim was to obtain efficiently antibodies which could react to both carcinoma and fetal cells. In this study we report one Mab, CF511, obtained using this novel approach, some biological properties of the antigen (CF511 antigen) and percentage incidence of the CF511 antigen in sera from ovarian carcinoma patients.
Materials and methods

Human tissues
Fresh normal and neoplastic adult tissues were obtained either at the time of surgery or at autopsy. Fetal tissues from around the tenth week of gestation were obtained during a therapeutic abortion in accordance with the guidelines (Ethicality of the limits to the use of organs from dead fetuses and neonates in research) of the Japanese Society of Obstetrics and Gynaecology.
Cell line
The human ovarian clear cell carcinoma cell line, HAC-2, which was provided by Dr M. Nishita, Tsukuba University school of Medicine, was maintained in vitro by conventional methods. Recently an HAC-2 cell clone was able to replicate continuously but slowly in a chemically defined, serum-free medium supplemented with Na2SeO3 (Nakabayashi et al., 1982) . No CA125 antigen was produced by HAC-2 cells under either set of culture conditions as determined by radioimmunoassay.
Cell and tissue extracts
Solid tissues were minced separately with scissors into small fragments and washed twice with 0.15 M NaCI solution. The tissue fragments were then placed into 10 volumes of ice-cold extraction buffer (10 mM Tris-HCI, pH 7.2, 0.15 M NaCI, 0.02% NaN3, 1 mM phenylmethylsulphonyl fluoride and 0.5% Nonidet P40) and homogenised with a Polytron homogeniser for 3 min on ice. Confluent monolayers of cultured cells were detacted by 0.02% EDTA in Dulbecco PBS(-), washed and resuspended in 10 volumes of ice-cold extraction buffer. The homogenates and cell suspension were then sonicated for 1 min, incubated for 20 min on ice, and centrifuged at 23,000g for 20 min at 0°C. The supernatants were kept frozen at -80°C until use. The protein concentrations of the extracts were determined by the method of Lowry et al. (1951) .
Production of Mabs BALB/c male mice were immunised 4-weekly with intraperitoneal (i.p.) injections of 2 mg protein of fetal extract emulsified in Freund's complete adjuvant. The extract was prepared from the homogenate of fetal tissues (excised liver and small intestine). Four weeks later the mice were given booster i.p. injections of 5 x 10' HAC-2 cells. Three days following the booster, the spleen cells from the immunised mice were fused by 50% polyethylene glycol (Boehringer Mannheim, FR Germany) with P3X63Ag8U-1 myeloma cells. Resulting hybrids were selected in HAT medium. Supernatants were initially screened for reactivity against HAC-2 cells using cell-target enzyme-linked immunosorbent assay (cell-ELISA). Target cell-coated plates were prepared as follows. HAC-2 cells, 2-3 x 104 per well, were cultured in tissue culture microplates (Corning no. 25860, USA) for 2-3 days to obtain a monolayer. Wells were gently washed once with PBS and then fixed with 0.05% glutaraldehyde (Sigma, USA) in PBS for 5 min at room temperature. For the saturation of free aldehyde groups they were incubated for 30 min with 1% bovine serum albumin (BSA, Sigma, USA) in 0.1 M glycine in PBS. Wells were washed twice with PBS and plates were incubated for 20 min with 0.3% (wt/vol) H202 in methanol for blocking the activity of endogenous peroxidase. Wells were blocked with Tris-buffered saline (TBS) containing 5% skimmed milk (Difco, USA) and 0.1% merthiolate for 2 h at room temperature or overnight at 4°C. Plates were washed twice with TBS containing 0.05% Tween 20 (T-TBS), and 50 yl of hybridoma culture supernatants were added and incubated for 4 h at room temperature. The wells were washed three times with T-TBS, followed by addition of 50 il horseradish peroxidase (HRP) labelled goat anti-mouse immunoglobulin (Ig) conjugate (Cappel, USA) diluted 1/1,000 in 5% skimmed milk in TBS and further incubated for 2 h at room temperature. After repeated five times washing, 150 ttl of O-phenylenediamine as a substrate was added and measured absorbence at 492 nm was determined after 20 min of colour development with a microplate reader (MPR A4 Toyo Soda, Japan). The hybridomas cloned by limiting dilution, expanded in vitro and were grown as an ascitic form in pristane-primed BALB/c mice. The spent culture media and ascites fluid were used as the source of antibody.
Immunoperoxidase staining Formalin fixed and paraffin embedded materials of common epithelial ovarian carcinomas and normal tissues were dewaxed, rehydrated through graded alcohol and blocked endogenous peroxidase by the conventional method by immersion in 0.3% H202 in methanol for 20 min. After washing in PBS, followed by treatment with normal horse serum, either hybridoma supernatants or Mab (10ILgml-') was incubated on each section for 60 min. The biotinylated anti-mouse Ig horse antibody (Vector, USA) followed by avidin-biotinylated HRP (Vector, USA) was applied for 30 min. Sections were incubated for a few minutes in peroxidase substrate (3,3' diaminobenzidine 4 HCI, DAB) solution. After being washed with distilled water, the sections were counter-stained with haematoxylin.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDSPAGE) and immunoblotting SDSPAGE was carried out by the discontinuous system of Laemmli, using 7.5% acrylamide gels under reducing conditions. Transfer of antigens to nitrocellulose paper was performed according to the method of Towbin et al. (1979) . Immunoblotting analysis was performed with residual binding sites which were blocked by incubation of blotted nitrocellulose paper with 5% skimmed milk in TBS, incubated with Mab CF511 culture supernatant at 4°C overnight, followed by incubation with properly HRP-conjugated antimouse Ig goat antibody (Cappel, USA) for 2 h at room temperature. The peroxidase activity was detected by exposing the membrane to 0.2mg ml-' of DAB, 0.01% H202 in TBS for 10 min. Gelfiltration HPLC system (TSK gel G-3000SW, 7.5 mm x 60 cm, Toyo Soda, Japan) was used. The column was equilibrated with 50 mM PB, pH 6.8, 0.25 M NaCl, at a flow rate of 0.43 ml min-'. The 
Purification of Mab CF511
Purification of Mab CF511 was performed by precipitation with 50% ammonium sulphate and gel filtration chromatography using Sephacryl S-300 (2.5 x 60 cm, buffered with TBS containing 0.02% NaN3, Pharmacia, Sweden), followed by HPLC (TSK gel G-4000SW, 7.7 mm x 60 cm, buffered with 50 mM PB, pH 6.8, 0.25 M NaCl, Toyo Soda, Japan (Figure 1 ). Levels of CFSJ1 antigen in patients' sera ELISA inhibition test was initially carried out. First, quantitative absorption of Mab CF511 was performed. The appropriate dilution of Mab was established in titring the antibody against HACCM(-) using the antigen coated-ELISA system. The dilution used in the absorption test was 1:10 (5 ,g ml-') and, by this test, the appropriate dilution of patients' sera was found to be 1:3 (Figure 2 ). The 1:10 diluted Mab CF511 was adapted to ELISA, and 1:3 diluted sera were treated for CF511 antigen levels by their ability to inhibit this ELISA signal according to the result of preincubation with the Mab CF51 1. Figure 3 shows the level of ELISA inhibition produced by a total of 219 sera from healthy volunteers, patients with common epithelial ovarian carcinoma, other carcinomas and benign diseases. The results Figure I SDSPAGE and immunoblot analysis of the antigen recognised by Mab CF511 (fetal extract (10 mg protein ml') of a, cell or tissue extract (0.1 mg protein ml-'); bl and c3, HAC-2 cells; b2, ovarian clear cellcarcinoma; b3, ovarian mucinous carcinoma; b4, ovarian serous carcinoma; b5, ovarian undifferentiated carcinoma; b6, hepatoma; b7, colon carcinoma; b8, gastric carcinoma; cl, thyroid gland; c2, lung; c4, kidney; c5, endometrium). (>), origin; Mol. wt, molecular weight; BPB, bromophenol blue. Figure 4 . More than 90% of the applied activity was detected in fractions eluting just after the elution volume of thyroglobulin (660 kDa). Figure I shows Figure 5 , the reactive bands to antibody were not found in the lanes of the samples derived from supernatants but only in those from precipitates (cell lystates). The results show that the binding ability of Mab CF511 to the antigen was partially destroyed by the treatment with neuraminidase. This result indicated that the antigenic sites recognised by Mab CF511 would contain sialic acid residues ( Figure 5 ). The same result was also demonstrated by antigen coated or cell-ELISA.
Pre-incubation of antigen for 1 h with neuraminidase resulted in a 55% decrease in ELISA signal (Table III) . However, trypsin treatment considerably increased the binding capacity of the antibody to defined antigen, separated by SDSPAGE, transblotted on the nitrocellulose paper; however, migration of the antigen into the gel markedly broadened and resulting bands were separated into four ( Figure 5 ). In contrast, treatment with proteinase K reduced the binding capacity of antibody to antigen on the nitrocellulose paper. However, weak but significant bands were noticeable. These findings suggested that some parts of the protein molecule might play a role in maintaining antigenicity. Since CF511 antigen was partially digested by trypsin without loss of the antigenicity, lysyl and arginyl bonds of peptide chains may not affect the antigenicity. The CF511 antigen was quite sensitive to 0.1 N NaOH and 2 M NaBH4 ( Figure 5) . Moreover, treatment with proteinase K, 0.1 N NaOH and 2 M NaBH4 failed to make detectably smaller molecular weight antigenic species. These findings may be because of inadequate transfer during the immunoblotting procedure of smaller fragments consisting mainly or entirely of carbohydrate. The CF5 11 antigen reactivity remained unchanged by heat treatment for 15min at 100°C (Table III) . By treatment with NaIO4, the immunoblotting analysis showed that the detection of the antigen demonstrated that CF511 binding to the antigen was not sensitive but increasing by the treatment with NaIO4; however, migration of the antigen into the gel decreased after this treatment, indicating that CF511 antigen contained carbohydrate chain and changes its conformation without decreasing antigenicity. After treatment with NaIO4, the antibody binding activity to antigen was also increased more than 70% of control when assay was carried out by antigen coated or cell-ELISA (Table III) . Since mild periodate oxidation at acidic pH has been shown to cleave carbohydrate vicinal hydroxyl groups without altering the structure of the polypeptide chains, the increased antibody binding upon periodate oxidation suggests that Mab CF511 may bind to the antigenic sites of peptide backbone rather than to that of carbohydrate molecules on the sialylated glycoprotein antigen.
Comparison of CF511 antigen with other tumour markers The reactivity of Mab CF511 was compared with those of Mab OC 125 (Bast et al., 1981) , DU-PAN-2 (Metzger et al., 1984) and DF3 (Hayes et al., 1985) , which recognised the peptide antigen in part, the sialylated carbohydrate antigen, as well as NS 19-9 (Koprowski et al., 1979) , FH 6 (Fukushi et al., 1984) and CSLEX1 (Fukushima et al., 1984) , which recognised the sialylated Lewisa, the sialylated Lewis'-i and sialylated Lewisx, respectively. Mab CF5 11 (5, 2, 0.5 fg ml-'1) Figure 5 CF511 antigen (HAC-2 cell) was treated with either enzymes or chemical reagents. After treatment of packed cells with each reagent, resulting supernatants and precipitates were then subjected to SDSPAGE followed by immunoblotting with Mab CF511 as described in Materials and methods. a, lane 1, PBS; 2, 0.125% trypsin (supernatant); 3, 0.125% trypsin (cell lysate); 4, proteinase K (I mg ml-, supernatant); 5, proteinase K (cell lysate); 6, NaOH/NaBH4 (mixture of supernatant and cell lysate). b, Cells in 10 mm acetate buffer pH 4.5 with (2) or without (1) 15 mm NaIO4. c, Cells in 10 mm acetate buffer, pH 6.5, 10 mm CaCl2 with (2, 2 h; 3, 1 h) or without (1) 0.1 mlL' neuraminidase.
was pre-incubated for 17 h at 4°C with each standard substance contained in each assay kit. Then each incubation mixture was assayed with inhibition ELISA assay as well as according to the presented usual manner mentioned in each kit. As shown in Table IV , Mab CF511 did not react with the standard substance of each assay kit and no remarkable competitive inhibition to make the standard curve for each assay system was observed (data not shown).
Discussion
Mab CF511 was raised by immunising mice with a tissue extract from 9-10-week-old fetus. The antibody binds to a 600kDa glycoprotein antigen found in many common epithelial ovarian carcinoma preparations as well as in the sera of many ovarian carcinoma patients. The occurrence of this antigen in patient sera has permitted the preparation of a competitive inhibition assay of ELISA signal using Mab CF51 1. aMab CF511 diluted by 1% BSA in TBS was pre-incubated with standard antigens, CA 19-9 (240 U ml-'), CA 15-3 (500 U ml-'), CA125 (500 U ml l'), DU-PAN-2 (1000 U ml -'), SLX (360 U ml1') and CSLEX (224 U ml-'), induced in the commercially available immunoassay kits. CF511 antigen (HACCM(-)) and normal mouse serum were used as negative and positive controls, respectively. Then the incubation mixtures were further incubated in antigen-coated microtitre wells and ELISA inhibition was estimated as described in Materials and methods. The former is mainly because of the abolition of the negative charge by desialylation of the sialylated glycoprotein where the high levels of sialic acid produce a significant negative charge on the SDS-glycoprotein complex. This curious phenomenon has been reported in other proteins, including high molecular weight tumour-associated glycoproteins (Gahmberg & Anderson, 1982; Johnson et al., 1986; Bray et al., 1987) . The latter is probably related to the conformational change of the antigen molecule due to cleavage of carbohydrate vicinal groups without altering the backbonepeptide chains . These findings suggest that the presence of several sialyl carbohydrate chains on a peptide backbone is probably required for maintaining CF511 antigenicity. However, it is difficult to ascertain the exact molecular properties of CF511 antigen from the data obtained from the treatment of non-purilfied antigen.
Purification of the antigen is currently under investigation.
Although may Mabs generated against ovarian carcinoma have been described, the possibility for sero-diagnosis of ovarian carcinoma is demonstrated in only one Mab reported (Bast et al., 1981 . The most useful marker for patients with common epithelial ovarian carcinoma has been developed as CA125, a glycoprotein of high molecular weight (over 200 kDa) (O'Brien et al., 1986; Masuho et al., 1984; Matsuoka et al., 1987) and probably in the range of 2-3 x 103 kDa by gel filtration determination (Davis et al., 1986) in nature by Mab OC125 raised against ovarian cancer cell line. The CA125 antigenic determinant was recognised as periodate-, neuraminidase-resistant and protease-, heatsensitive. These data strongly suggest that the CA 125 antigenic determinant is composed, at least in part, of conformationally dependent peptide and is different from those of CF511 antigen. Bast et al. (1983) reported that elevated CA125 antigen levels could be detected in serum of more than 80% of patients with common epithelial ovarian carcinomas and that levels correlated with progression or regression of the diseases. However, CA125 has been found to be expressed not only in epithelial ovarian neoplasms but also in the derivatives of the coelomic epithelium, such as the muellerian epithelium, the linging cells from the coelomic cavity and lung tissues (O'Brien et al., 1986; Kabawat et al., 1983; Masuho et al., 1984; Matsuoka et al., 1987; Nouwen et al., 1986) . Serum levels of CA125 are therefore increased in a number of non-ovarian carcinoma patients including those with lung carcinoma and in some benign chronic pathologies (Nouwen et al., 1986; Niloff et al., 1984) . In immunohistological analysis, CF511 antigen was present in common epithelial ovarian carcinoma (serous (100%), clear cell (100%), endometrioid (100%), and undifferentiated carcinoma (100%), mucinous (50%)) as well as in normal lung, breast, fallopian tube, uterus and thyroid gland. Serum levels of CF511 antigen are significantly elevated not only in ovarian carcinoma patients but also in either breast carcinoma or lung carcinoma patients regardless of the histological patterns. In contrast, no remarkable elevation of antigen levels was noted in patients with gastric carcinoma or with hepatoma and colorectal carcinoma. Furthermore, the incidence of false-positive reaction of CF511 antigen in patients with endometriosis was very much lower (22%) than that for the CA125 detection system (Niloff et al., 1984) . These results clearly indicate that CF511 antigen is distinct from CA 125 and may be a generally useful marker for diagnosis and monitoring diseases in patients with common epithelial carcinoma as well as lung cell carcinoma and breast carcinoma.
It has been reported that some Mabs, originated against carcinomas derived from other organs, also cross-reacted with human ovarian carcinomas (Thor et al., 1986; Friedman et al., 1986) . The most useful serodiagnostic Mab among these is known as DF3, and is prepared against a human breast carcinoma (Hayes et al., 1985) . However, two distinct differences in molecular characteristics between CF511 antigen and DF3 antigen are noticeable. The circulating CF511 antigen is highly detectable (10/10, 100%) in sera from patients with lung carcinoma, regardless of histology, whereas only 1/11 (9.1%) patients with lung carcinoma had DF3 positively detectable antigen levels (Friedman et al., 1986) . Another obvious difference between CF511 antigen and DF3 antigen is found in molecular weight determination using SDSPAGE-immunoblot analysis and/or gel filtration. DF3 identified a glycoprotein with a heterogenous molecular weight ranging from 300 to 450 kDa (Friedman et al., 1986; Hayes et al., 1985; Sekine et al., 1985) , whereas Mab CF511 recognises a band corresponding to a molecular weight of more than 600 kDa glycoprotein. Furthermore, by using competitive inhibition assay, the Mab CF511 and some antibodies against well characterised tumour marker antigens (CA19-9, CA125, CA15-3, DU-PAN-2, SLX, CSLEX) clearly react with different antigen epitope. These results suggest that the CF511 antigen does not seem to be related to previously characterised antigens.
Although Mab CF511 was prepared using fetal tissue ex-tract from early first trimester as an immunogen followed by booster injection using human ovarian cancer cell line, HAC-2, the raising antigen, is not specific for fetal tissues and ovarian carcinomas, but is present on a few normal adult tissues and their derived carcinomas. Additionally, the antigen contents of various tissue extracts from normal adult are much higher than in those from fetus, as determined by antigen coated-ELISA as well as immunoblot analysis. Particularly, the antigen content in lung tissue is the same as that of common epithelial ovarian carcinoma. Despite the restricted distribution in some organs from normal adult, CF511 antigen circulates at significantly lower levels in normal individuals than in patients with carcinoma. These results suggest that the antigen is a normal tissue antigen that is anomalously shed or secreted into the circulation of epithelial ovarian carcinoma, lung carcinoma and breast carcinoma patients. Although the initial purpose of obtaining a Mab directed towards onco-developmental antigens was not accomplished in this investigation, the strategy used here may be useful in the generation of new antibodies againsts oncodevelopmental antigens as well as cancer associated antigens. Such antibodies may be useful as tumour markers.
